CXCR4

Class

Small molecule (cyclic peptide, CXCR4 antagonist)

Pathway

CXCR4/CXCL12 (SDF-1) axis blockade — mobilizes hematopoietic stem/progenitor cells from bone marrow niche into peripheral blood

CXCR4 is a G protein–coupled receptor expressed on hematopoietic stem and progenitor cells, certain immune cells, and many tumor cells. Its natural ligand, the chemokine CXCL12 (also called SDF-1), is produced by stromal cells within the bone marrow niche. Binding of CXCL12 to CXCR4 anchors stem cells in the marrow and helps recruit immune cells to sites of inflammation or malignancy. Small molecules and cyclic peptides that antagonize CXCR4 block this interaction, disrupting the retention signal and causing hematopoietic stem and progenitor cells to leave the marrow and enter the bloodstream, a process called mobilization. This is clinically useful when stem cells need to be collected from peripheral blood, such as for transplantation procedures. Beyond mobilization, the CXCR4/CXCL12 axis is implicated in cancer biology, where tumor cells exploit the same signaling to home to marrow niches, evade immune surveillance, or seed metastases, and in fibrotic and inflammatory diseases where aberrant chemokine signaling sustains cell recruitment. CXCR4 antagonism is therefore explored both as a supportive mobilization strategy and, more speculatively, as a way to interfere with tumor–stroma interactions or immune cell trafficking in solid tumors and hematologic malignancies.